Phase 2 trial in 64 patients with cutaneous lichen planus: 50.0% on ruxolitinib 1.5% cream vs 21.9% on vehicle reached IGA treatment success at week 16 (difference 29.4%, P=.01). No serious treatment-emergent adverse events with ruxolitinib.
RCTn = 64
Mangold et al. Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial